What liver problems should we pay attention to when using pitobrutinib?

Pirtobrutinib is a selective BTK inhibitor mainly used to treat diseases such as chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Although pitobrutinib has significant antitumor activity, its use requires special attention, especially in the liver. The following are some liver-related considerations when using pitobrutinib.
1. Liver function monitoring: Pitobrutinib may have a certain impact on the liver during treatment. Therefore, patients need to regularly monitor liver function during treatment, including measuring liver enzymes (such as ALT, AST) and bilirubin levels. Especially for those patients with abnormal liver function, doctors need to conduct a detailed liver function assessment before starting treatment, and adjust the dose or conduct further examinations according to the situation. For patients whose liver function is severely affected, treatment suspension or other interventions may be necessary.

2. Hepatotoxic reactions: Pitobrutinib, like other BTK inhibitors, may cause hepatotoxic reactions. Although such side effects are relatively rare, some patients may still experience abnormal liver function or liver-related symptoms, such as jaundice and upper abdominal discomfort. If patients develop these symptoms during treatment, they should report to the doctor as soon as possible and take necessary intervention measures. If liver toxicity is severe, medication may need to be stopped and appropriate treatment given to relieve symptoms.

3. Medication adjustment for patients with liver disease: Patients with a history of liver disease need to be more careful when using pitobrutinib. If the patient has underlying liver diseases such as cirrhosis and hepatitis, the use of this drug may increase the burden on the liver, thereby exacerbating the risk of liver damage. In these patients, dose adjustment or even avoidance of pitobrutinib may be considered. During treatment, doctors should carefully assess the risks based on the severity of the liver disease and adjust the treatment plan according to the patient's specific situation.
4. Hepatic metabolism of Pitobrutinib: The metabolism of Pitobrutinib in the body is mainly carried out by the liver, so the state of liver function directly affects the metabolism and clearance of the drug. Patients with liver insufficiency may increase the concentration of the drug in the body, thereby increasing the chance of side effects. Therefore, caution should be used when using pitobrutinib in patients with liver disease, especially those with moderate to severe hepatic impairment, and dose adjustment or alternative treatment options may be necessary. Regular liver function tests are essential to assess drug metabolism and ensure the safety of treatment.
Overall, although the hepatotoxicity of pitobrutinib is relatively low, liver function still needs to be closely monitored during use, especially for patients with existing liver problems. The risk of adverse liver reactions can be minimized through regular monitoring and timely adjustments to treatment regimens.